

# Adrian Ciurea

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6162032/publications.pdf>

Version: 2024-02-01

59  
papers

2,794  
citations

304368

22  
h-index

182168

51  
g-index

60  
all docs

60  
docs citations

60  
times ranked

3231  
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to "Correspondence on "Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort"™ by Ruysse-Witrand et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e33-e33.	0.5	4
2	Response to: "Correspondence on "Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort"™ by Micheroli et al"™</i> by Huang et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e227-e227.	0.5	0
3	TNF± induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNF± antibodies. Cardiovascular Research, 2022, 118, 254-266.	1.8	13
4	Role of synovial fibroblast subsets across synovial pathotypes in rheumatoid arthritis: a deconvolution analysis. RMD Open, 2022, 8, e001949.	1.8	23
5	Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort. RMD Open, 2022, 8, e002067.	1.8	11
6	The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. Rheumatology, 2022, 61, 4741-4751.	0.9	6
7	European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. Rheumatology, 2022, 61, 3799-3807.	0.9	7
8	Prediction of histology by B-mode and PD-mode ultrasound across different joint locations and diseases. RMD Open, 2022, 8, e002439.	1.8	0
9	Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Annals of the Rheumatic Diseases, 2021, 80, 238-241.	0.5	54
10	Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA for the severity of rheumatoid arthritis. Rheumatology, 2021, 60, 4598-4608.	0.9	15
11	Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors. Rheumatology, 2021, 61, 131-138.	0.9	8
12	Impact of assessing patient-reported outcomes with mobile apps on patient-provider interaction. RMD Open, 2021, 7, e001566.	1.8	14
13	Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Annals of the Rheumatic Diseases, 2021, 80, 1410-1418.	0.5	28
14	Site-specific resolution of enthesitis in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors. Arthritis Research and Therapy, 2021, 23, 165.	1.6	2
15	Ossification of the ligamentum flavum. Rheumatology, 2020, 59, 1616-1616.	0.9	6
16	Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort. Arthritis Research and Therapy, 2020, 22, 233.	1.6	32
17	Travel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to controls: A multi-centre, observational study. Travel Medicine and Infectious Disease, 2020, 38, 101818.	1.5	1
18	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. Annals of the Rheumatic Diseases, 2020, 79, 1423-1431.	0.5	11

#	ARTICLE	IF	CITATIONS
19	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. <i>RMD Open</i> , 2020, 6, e001280.	1.8	33
20	Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort. <i>PLoS ONE</i> , 2020, 15, e0230268.	1.1	17
21	Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1203-1209.	0.5	37
22	Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14868 patients with spondyloarthritis. <i>Rheumatology</i> , 2020, 59, 2455-2461.	0.9	7
23	Barriers and Facilitators of Vigorous Cardiorespiratory Training in Axial Spondyloarthritis: Surveys Among Patients, Physiotherapists, and Rheumatologists. <i>Arthritis Care and Research</i> , 2019, 71, 839-851.	1.5	23
24	Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1545-1549.	0.5	71
25	Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1536-1544.	0.5	58
26	Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis. <i>PLoS ONE</i> , 2019, 14, e0216746.	1.1	7
27	Oligomeric S100A4 Is Associated With Monocyte Innate Immune Memory and Bypass of Tolerance to Subsequent Stimulation With Lipopolysaccharides. <i>Frontiers in Immunology</i> , 2019, 10, 791.	2.2	33
28	The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort. <i>PLoS ONE</i> , 2019, 14, e0211554.	1.1	15
29	Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases—a prospective multi-centre cohort study. <i>Rheumatology</i> , 2019, 58, 1585-1596.	0.9	19
30	FRI0144—JOINT-SPECIFIC RESPONSES TO TOFACITINIB AND ADALIMUMAB IN RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STANDARD AND ORAL STRATEGY. , 2019, , .		0
31	OP0105—HPR DO MOBILE APPS IMPROVE SHARED DECISION MAKING AND DISEASE MANAGEMENT IN THE RHEUMATIC DISEASES? AN EVALUATION OF APPS IN A SWISS RHEUMATOLOGY REGISTRY. , 2019, , .		2
32	OP0221—OLIGOMERIC S100A4 INDUCES MONOCYTE INNATE IMMUNE MEMORY. , 2019, , .		0
33	FRI0375—SITE-SPECIFIC EFFECTIVENESS OF TNF INHIBITORS FOR ENTHESITIS IN DMARD-NAIVE PATIENTS WITH AXIAL SPONDYLOARTHRITIS. , 2019, , .		1
34	OP0031—ARE THE MODIFIED NEW YORK AND ASAS AXIAL SPONDYLOARTHRITIS CRITERIA INTERCHANGEABLE IN THE CLASSIFICATION OF SPONDYLOARTHRITIS PATIENTS WITH RADIOGRAPHIC SACROILIITIS: COMPARISON IN 8 COHORTS?. , 2019, , .		0
35	Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. <i>Journal of Rheumatology</i> , 2018, 45, 506-512.	1.0	31
36	Can Ultrasound Be Used to Predict Loss of Remission in Patients with RA in a Real-life Setting? A Multicenter Cohort Study. <i>Journal of Rheumatology</i> , 2018, 45, 887-894.	1.0	14

#	ARTICLE	IF	CITATIONS
37	TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 63-69.	0.5	220
38	Redox-Mediated Mechanisms Fuel Monocyte Responses to CXCL12/HMGB1 in Active Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2018, 9, 2118.	2.2	40
39	Evaluating the bromodomain protein BRD1 as a therapeutic target in rheumatoid arthritis. <i>Scientific Reports</i> , 2018, 8, 11125.	1.6	13
40	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 978-991.	0.5	1,220
41	The epigenetic architecture at gene promoters determines cell type-specific LPS tolerance. <i>Journal of Autoimmunity</i> , 2017, 83, 122-133.	3.0	25
42	Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 1579-1585.	0.9	63
43	Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 164.	1.6	69
44	Expression and Regulation of PIWIL-Proteins and PIWI-Interacting RNAs in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0166920.	1.1	22
45	The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2141-2150.	2.9	25
46	Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. <i>Arthritis Research and Therapy</i> , 2016, 18, 71.	1.6	34
47	Effect of rituximab on pulmonary function in patients with rheumatoid arthritis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 37, 24-29.	1.1	14
48	Impaired response to treatment with tumour necrosis factor $\pm$ inhibitors in smokers with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 532-539.	0.5	45
49	HLA-B27-Homodimer-Specific Antibody Modulates the Expansion of Pro-Inflammatory T-Cells in HLA-B27 Transgenic Rats. <i>PLoS ONE</i> , 2015, 10, e0130811.	1.1	9
50	Correlation of findings in clinical and high resolution ultrasonography examinations of the painful shoulder. , 2015, 15, 29-44.		17
51	Treatment with Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Comparison Between Private Rheumatology Practices and Academic Centers in a Large Observational Cohort. <i>Journal of Rheumatology</i> , 2015, 42, 101-105.	1.0	12
52	Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria. <i>Rheumatology International</i> , 2015, 35, 295-302.	1.5	7
53	Age at symptom onset in ankylosing spondylitis: is there a gender difference?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1908-1910.	0.5	19
54	BAFF levels in patients with ankylosing spondylitis and response to anti-tumor necrosis factor treatment. <i>Joint Bone Spine</i> , 2013, 80, 433-434.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Smoking and spondyloarthritis. <i>Joint Bone Spine</i> , 2013, 80, 234-235.	0.8	15
56	Tumor Necrosis Factor $\hat{\pm}$ Inhibition in Radiographic and Nonradiographic Axial Spondyloarthritis: Results From a Large Observational Cohort. <i>Arthritis and Rheumatism</i> , 2013, 65, 3096-3106.	6.7	129
57	Impairment of Cd4+ T Cell Responses during Chronic Virus Infection Prevents Neutralizing Antibody Responses against Virus Escape Mutants. <i>Journal of Experimental Medicine</i> , 2001, 193, 297-306.	4.2	86
58	Viral escape from the neutralizing antibody response: the lymphocytic choriomeningitis virus model. <i>Immunogenetics</i> , 2001, 53, 185-189.	1.2	30
59	CD4+ T-cellâ€™epitope escape mutant virus selected in vivo. <i>Nature Medicine</i> , 2001, 7, 795-800.	15.2	72